These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

282 related items for PubMed ID: 30366769

  • 1. The KIF5B-RET Fusion Gene Mutation as a Novel Mechanism of Acquired EGFR Tyrosine Kinase Inhibitor Resistance in Lung Adenocarcinoma.
    Zhu YC, Wang WX, Zhang QX, Xu CW, Zhuang W, Du KQ, Chen G, Lv TF, Song Y.
    Clin Lung Cancer; 2019 Jan; 20(1):e73-e76. PubMed ID: 30366769
    [No Abstract] [Full Text] [Related]

  • 2. [The progress of KIF5B-RET fusion gene in non-small cell lung cancer].
    Jin LL, Kong H, Xie WP.
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Jul; 36(7):524-6. PubMed ID: 24262090
    [No Abstract] [Full Text] [Related]

  • 3. Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion.
    Tsai TH, Wu SG, Hsieh MS, Yu CJ, Yang JC, Shih JY.
    Lung Cancer; 2015 May; 88(2):208-14. PubMed ID: 25773866
    [Abstract] [Full Text] [Related]

  • 4. A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma.
    Hida T, Velcheti V, Reckamp KL, Nokihara H, Sachdev P, Kubota T, Nakada T, Dutcus CE, Ren M, Tamura T.
    Lung Cancer; 2019 Dec; 138():124-130. PubMed ID: 31710864
    [Abstract] [Full Text] [Related]

  • 5. Diagnostic method for the detection of KIF5B-RET transformation in lung adenocarcinoma.
    Go H, Jung YJ, Kang HW, Park IK, Kang CH, Lee JW, Ju YS, Seo JS, Chung DH, Kim YT.
    Lung Cancer; 2013 Oct; 82(1):44-50. PubMed ID: 23932363
    [Abstract] [Full Text] [Related]

  • 6. Developments for Personalized Medicine of Lung Cancer Subtypes: Mass Spectrometry-Based Clinical Proteogenomic Analysis of Oncogenic Mutations.
    Nishimura T, Nakamura H.
    Adv Exp Med Biol; 2016 Oct; 926():115-137. PubMed ID: 27686809
    [Abstract] [Full Text] [Related]

  • 7. Lung adenocarcinoma harboring concomitant EGFR mutation and EML4-ALK fusion that benefits from three kinds of tyrosine kinase inhibitors: a case report and literature review.
    Zhao N, Zheng SY, Yang JJ, Zhang XC, Xie Z, Xie B, Su J, Chen ZH, Chen SL, Zhang N, Lou NN, Dong S, Wu YL.
    Clin Lung Cancer; 2015 Mar; 16(2):e5-9. PubMed ID: 25496960
    [No Abstract] [Full Text] [Related]

  • 8. KIF5B-RET fusions in lung adenocarcinoma.
    Kohno T, Ichikawa H, Totoki Y, Yasuda K, Hiramoto M, Nammo T, Sakamoto H, Tsuta K, Furuta K, Shimada Y, Iwakawa R, Ogiwara H, Oike T, Enari M, Schetter AJ, Okayama H, Haugen A, Skaug V, Chiku S, Yamanaka I, Arai Y, Watanabe S, Sekine I, Ogawa S, Harris CC, Tsuda H, Yoshida T, Yokota J, Shibata T.
    Nat Med; 2012 Feb 12; 18(3):375-7. PubMed ID: 22327624
    [Abstract] [Full Text] [Related]

  • 9. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.
    Ju YS, Lee WC, Shin JY, Lee S, Bleazard T, Won JK, Kim YT, Kim JI, Kang JH, Seo JS.
    Genome Res; 2012 Mar 12; 22(3):436-45. PubMed ID: 22194472
    [Abstract] [Full Text] [Related]

  • 10. Detection of RET (rearranged during transfection) variants and their downstream signal molecules in RET rearranged lung adenocarcinoma patients.
    Kim JO, Shin JY, Kim MY, Son KH, Jung CK, Kim TJ, Kim SY, Park JK, Sung SW, Bae SJ, Min HJ, Kang JH.
    Surg Oncol; 2018 Mar 12; 27(1):106-113. PubMed ID: 29549897
    [Abstract] [Full Text] [Related]

  • 11. Next-generation Sequencing Identified a Novel WDPCP-ALK Fusion Sensitive to Crizotinib in Lung Adenocarcinoma.
    He Z, Wu X, Ma S, Zhang C, Zhang Z, Wang S, Yu S, Wang Q.
    Clin Lung Cancer; 2019 Sep 12; 20(5):e548-e551. PubMed ID: 31281052
    [No Abstract] [Full Text] [Related]

  • 12. KIF5B/RET fusion gene in surgically-treated adenocarcinoma of the lung.
    Yokota K, Sasaki H, Okuda K, Shimizu S, Shitara M, Hikosaka Y, Moriyama S, Yano M, Fujii Y.
    Oncol Rep; 2012 Oct 12; 28(4):1187-92. PubMed ID: 22797671
    [Abstract] [Full Text] [Related]

  • 13. RET fusion gene: translation to personalized lung cancer therapy.
    Kohno T, Tsuta K, Tsuchihara K, Nakaoku T, Yoh K, Goto K.
    Cancer Sci; 2013 Nov 12; 104(11):1396-400. PubMed ID: 23991695
    [Abstract] [Full Text] [Related]

  • 14. Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.
    Huang Q, Schneeberger VE, Luetteke N, Jin C, Afzal R, Budzevich MM, Makanji RJ, Martinez GV, Shen T, Zhao L, Fung KM, Haura EB, Coppola D, Wu J.
    Mol Cancer Ther; 2016 Oct 12; 15(10):2521-2529. PubMed ID: 27496134
    [Abstract] [Full Text] [Related]

  • 15. A Patient With Lung Adenocarcinoma With BRAF Gene Fusion and Response to Vemurafenib.
    Zhu YC, Wang WX, Xu CW, Zhuang W, Du KQ, Chen G, Lv TF, Song Y.
    Clin Lung Cancer; 2019 May 12; 20(3):e224-e228. PubMed ID: 30914311
    [No Abstract] [Full Text] [Related]

  • 16. KIF5B-RET Fusion gene may coincide oncogenic mutations of EGFR or KRAS gene in lung adenocarcinomas.
    Kim JO, Lee J, Shin JY, Oh JE, Jung CK, Park JK, Sung SW, Bae SJ, Min HJ, Kim D, Park JY, Kang JH.
    Diagn Pathol; 2015 Aug 14; 10():143. PubMed ID: 26268359
    [Abstract] [Full Text] [Related]

  • 17. A case of EGFR mutation-positive lung adenocarcinoma in which the T790M allele fraction was increased by repeated EGFR-TKI treatment.
    Kimura H, Amino Y, Koba H, Tambo Y, Ohkura N, Hara J, Sone T, Kasahara K.
    Cancer Commun (Lond); 2019 Nov 01; 39(1):67. PubMed ID: 31675980
    [No Abstract] [Full Text] [Related]

  • 18. Whole-exome sequencing explored mechanism of selpercatinib resistance in RET-rearranged lung adenocarcinoma transformation into small-cell lung cancer: a case report.
    Peng Y, Zheng Z, Zewen W, Yanan L, Mingyan Z, Meili S.
    BMC Pulm Med; 2023 Dec 06; 23(1):492. PubMed ID: 38057798
    [Abstract] [Full Text] [Related]

  • 19. A Case of Novel Inversion Mutation of EGFR Exon 19 Leading to Primary Resistance to EGFR TKIs in Lung Adenocarcinoma.
    Li S, Zhao J, Wang Q.
    J Thorac Oncol; 2018 Jun 06; 13(6):e97-e101. PubMed ID: 29501421
    [No Abstract] [Full Text] [Related]

  • 20. Identification of a Novel KIF5B-RET, ABHD17C-RET Double-Fusion Variant in Lung Adenocarcinoma and Response to Cabozantinib.
    Zheng Q, Fang W, Huang Y, Gan J, Zhang L.
    J Thorac Oncol; 2020 Aug 06; 15(8):e132-e133. PubMed ID: 32718536
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.